1. Introduction {#sec1-cancers-11-01382}
===============

Radioactive iodine I-131 (RAI) is a cornerstone in the routine adjuvant management in patients with high-risk differentiated thyroid cancer (DTC) \[[@B1-cancers-11-01382]\]; however, 5% to 15% of DTC and 50% of metastatic DTCs are refractory to RAI treatment \[[@B2-cancers-11-01382],[@B3-cancers-11-01382],[@B4-cancers-11-01382]\]. Patients with RAI-refractory (RAI-R) thyroid cancer have poor outcomes, with 5-year disease-specific survival rates of 60% to 70% \[[@B5-cancers-11-01382]\]. Those with RAI-R metastatic thyroid cancer have the worst outcomes, with a 10-year survival rate of 10% \[[@B6-cancers-11-01382]\]. Hence, resensitizing RAI-R tumors to RAI can potentially improve survival for patients with DTC.

With recent advances and developments in understanding of the oncogenic pathways involved in the development of thyroid cancers and the molecular basis of RAI refractoriness, targeted therapies are being developed and are showing promising results \[[@B7-cancers-11-01382],[@B8-cancers-11-01382],[@B9-cancers-11-01382],[@B10-cancers-11-01382]\]. Here, we review the molecular mechanisms underlying RAI refractoriness, describe targeted therapies that may overcome these mechanisms, and explore promising therapeutic regimens to improve outcomes in RAI-R thyroid cancers.

2. Definition of RAI-R Tumors {#sec2-cancers-11-01382}
=============================

A major obstacle to standardizing the approach to RAI-R tumors is the lack of a consistent definition for RAI-R. The following definitions for RAI-R tumors are used in the literature \[[@B11-cancers-11-01382],[@B12-cancers-11-01382],[@B13-cancers-11-01382]\]:i.Absence of RAI uptake at initial diagnosis of locoregional recurrence or distant metastasis;ii.Absence or progressive loss of radioiodine uptake in the post-therapy scan several days after RAI therapy;iii.Presence of more than 1 metastatic lesion with at least one lesion without RAI uptake in the post-therapy scan;iv.Structural progression of tumors 12 to 16 months after RAI therapy despite the presence of iodine uptake in the post-therapy scan;v.Tumors in patients who have received 600 millicurie (mCi)/22.2 gigabecquerel (GBq) or more of RAI cumulatively without signs of remission;viSignificant uptake on 2-deoxy-2-\[fluorine-18\] fluoro-D-glucose positron emission tomography integrated with computed tomography (F-18 FDG PET/CT).

None of the above criterion alone portends that a tumor is RAI-R, rather it predicts the likelihood that a tumor will be RAI-refractory and should be used together for risk stratification of the tumors in assessing for refractoriness. It is important for the RAI uptake scan to be standardized and an optimal approach is required for patient preparation and choice of imaging modality \[[@B14-cancers-11-01382]\].

Aggressive or poorly differentiated tumors on histology or tumors exhibiting aggressive genetic profiles (such as *BRAF* and telomerase reverse transcriptase (*TERT*) promoter mutation) can also be included for risk stratification of patients \[[@B15-cancers-11-01382]\].

3. Molecular Mechanisms Driving Primary RAI Refractoriness {#sec3-cancers-11-01382}
==========================================================

RAI refractoriness most frequently develops in the context of loss of thyroid differentiation features. One hallmark of dedifferentiation is impairment of Na/I symporter (NIS) function \[[@B16-cancers-11-01382],[@B17-cancers-11-01382]\]. NIS is a plasma membrane glycoprotein, a member of solute carrier family 5A (*SLC5A5*), located on the basolateral surface of the thyroid follicular epithelial cells. NIS mediates active iodide transport into thyroid follicular cells, and in the normal thyroid cells, Thyroid stimulating hormone (TSH) stimulates NIS expression via the cyclic adenosine monophosphate (cAMP) pathway, binding to the NIS promoter via paired box 8 (PAX8) \[[@B18-cancers-11-01382]\]. The ability of follicular cells to concentrate iodine is exploited in thyroid cancer therapy; RAI enters the cells via NIS and emits beta particles that destroy the follicular cell \[[@B16-cancers-11-01382],[@B19-cancers-11-01382]\]. In a subset of DTCs, impaired targeting to the plasma membrane or impaired intracellular retention of NIS results in NIS loss, producing RAI resistance \[[@B20-cancers-11-01382]\]. [Figure 1](#cancers-11-01382-f001){ref-type="fig"} summarizes the transcriptional and translational pathways involved in regulation of NIS expression. By deconvoluting the mechanisms involved in NIS downregulation or loss of function in thyroid cancer, it is possible to identify targets that could potentially overcome RAI refractoriness in thyroid cancers \[[@B17-cancers-11-01382],[@B20-cancers-11-01382]\].

Genetic and epigenetic alterations in the RTK/BRAF/MAPK/ERK and PI3K-AKT-mTOR pathways by acquired point mutations, chromosomal rearrangement, or aberrant gene methylation underly the diminished NIS signaling central to RAI refractoriness \[[@B21-cancers-11-01382],[@B22-cancers-11-01382],[@B23-cancers-11-01382]\]. The most well-defined example of a point mutation aberrantly activating these signaling pathways is the activating hotspot *BRAF^V600E^* mutation. *BRAF^V600E^* represents the most frequent genetic aberration in thyroid cancers, occurring in nearly 50% of DTCs. *BRAF^V600E^* mutations both inversely correlate with NIS expression and directly correlate with dedifferentiation, recurrence, and metastasis \[[@B24-cancers-11-01382],[@B25-cancers-11-01382]\]. BRAF activation has been found to repress NIS expression via two defined pathways. First, BRAF activates TGFβ (Transforming growth factor β)/Smad3 signaling, which directly impairs the ability of the thyroid-specific transcription factor PAX8 (paired box gene 8) to bind the *NIS* promoter in follicular cells \[[@B26-cancers-11-01382]\]. Second, BRAF epigenetically regulates *NIS* by driving histone deacetylation of the H3 and H4 lysine residues of the *NIS* promoter, directly preventing its transcription \[[@B27-cancers-11-01382]\].

4. Management of RAI-R Thyroid Cancers {#sec4-cancers-11-01382}
======================================

4.1. Monitoring and Watchful Waiting {#sec4dot1-cancers-11-01382}
------------------------------------

RAI-R metastatic DTCs can be asymptomatic for several years \[[@B28-cancers-11-01382]\]. Active surveillance and watchful waiting with TSH suppression can be employed in patients with asymptomatic disease, low tumor burden or tumor size less than 1 cm, and minimally progressive tumors \[[@B12-cancers-11-01382],[@B13-cancers-11-01382],[@B29-cancers-11-01382],[@B30-cancers-11-01382]\]. Presence of small (\<8 mm) and asymptomatic metastatic lymph nodes after RAI therapy with previous neck compartmental dissection and small (\<1 cm) metastatic pulmonary nodules can be followed up for years with neck ultrasonography and axial imaging for the pulmonary nodules. Other imaging modalities, such as F-18 FDG PET/CT, and thyroglobulin levels in TSH-suppressed patients can also be used to assess disease progression \[[@B12-cancers-11-01382],[@B13-cancers-11-01382],[@B31-cancers-11-01382],[@B32-cancers-11-01382],[@B33-cancers-11-01382]\]; these are used in conjunction with axial imaging when growth of lesions is suspected \[[@B34-cancers-11-01382]\].

4.2. Local Therapy {#sec4dot2-cancers-11-01382}
------------------

In locoregional relapse, surgery is still the most commonly used therapeutic approach, with therapeutic compartmental central or lateral neck dissection to spare uninvolved vital structures, or a more limited surgery in cases of prior comprehensive neck dissection \[[@B12-cancers-11-01382],[@B13-cancers-11-01382]\]. External-beam radiation therapy (EBRT) is commonly used alone or in combination with surgery in bone and central nervous system (CNS) metastasis of thyroid cancers \[[@B35-cancers-11-01382],[@B36-cancers-11-01382]\]. Some studies have demonstrated benefit in locoregional control and good prognosis with surgery combined with EBRT in doses of 40 to 50 Gy in patients 45 years and older \[[@B37-cancers-11-01382]\]. Limited outcome data are available on other locoregional therapies, such as radiofrequency ablation, and ethanol ablation or embolization \[[@B13-cancers-11-01382]\]. It is of note that symptomatic patients with metastatic lung nodules or bone lesions are usually considered for local therapies before systemic therapies \[[@B38-cancers-11-01382]\].

4.3. Targeted Therapies Using Tyrosine Kinase Inhibitors {#sec4dot3-cancers-11-01382}
--------------------------------------------------------

Targeted treatments for thyroid cancer have been increasingly developed over the last decade along with increasing knowledge about the disease's underlying molecular alterations. Most agents that were tested in phase II and III trials were developed for treatment of advanced RAI-R thyroid cancer.

Cellular dedifferentiation in thyroid cancers causes tumor progression in the form of more aggressive growth, metastasis, loss of iodide uptake, or unresponsiveness to RAI therapy, and correlates with the degree of MAPK activation. Tyrosine kinases are involved in the MAPK signaling pathway through phosphorylation/dephosphorylation of several intracellular proteins, which underlies the rationale for the use of tyrosine kinase inhibitors (TKIs) in the treatment of thyroid cancer \[[@B21-cancers-11-01382],[@B39-cancers-11-01382]\].

TKIs have been shown to significantly improve progression-free survival rates in advanced RAI-R DTCs. Overall survival has been difficult to document in these trials, likely because patients cross over to the drug arm once disease progression is documented in the control group \[[@B9-cancers-11-01382],[@B10-cancers-11-01382]\]. An overall survival benefit was observed with the use of lenvatinib in selected patients \> 65 years of age with RAI-R DTCs \[[@B40-cancers-11-01382]\]. Two TKIs, lenvatinib and sorafenib, are currently used for the treatment of RAI-R DTC ([Table 1](#cancers-11-01382-t001){ref-type="table"}), and two others, vandetanib (NCT01876784) and cabozantinib (NCT03690388), are under investigation in phase III trials for patients with progressive RAI-R DTCs and advanced RAI-R DTCs unresponsive to previous VEGFR therapy, respectively \[[@B41-cancers-11-01382],[@B42-cancers-11-01382]\].

Although TKIs have revolutionized the field of targeted therapy in RAI-R DTC patients, these agents are usually administered lifelong, and several drawbacks were associated with their long-term application. TKIs' adverse effect profiles have a great impact on quality of life and should be taken into consideration by the clinician prior to treatment initiation. Also, a resistance to the treatment, also called "escape", can develop; hence, access and adherence to close monitoring with a continuous assessment of adverse effects and the patient's quality of life should be considered in the decision to start the therapy \[[@B43-cancers-11-01382]\]. In clinical settings with no preselection of patients, lenvatinib has been shown to be useful in the management of RAI-R DTCs with implementation of good and specified management protocols for toxicities and adverse events \[[@B44-cancers-11-01382],[@B45-cancers-11-01382]\].

Potential targets are also transcriptional factors such as vascular endothelial growth factor (VEGF). In response to intratumoral hypoxia, hypoxia inducible factor-1 alpha (HIF-1α) is activated and induces VEGF transcription together with co-stimulation by growth factor signaling pathways, such as the PI3K/AKT and MAPK pathways \[[@B46-cancers-11-01382],[@B47-cancers-11-01382]\]. VEGF is a promoter of angiogenesis and is an attractive target for therapy. Another target for HIF-1α is the MET oncogene, which is overexpressed in thyroid cancers, especially medullary thyroid cancer (MTC), thereby promoting angiogenesis, cellular motility, invasion, and metastasis \[[@B48-cancers-11-01382],[@B49-cancers-11-01382]\].

4.4. Tumoral Escape Mechanisms from Targeted Therapies {#sec4dot4-cancers-11-01382}
------------------------------------------------------

As discussed above, thyroid cancers often become RAI-R by co-opting RAF and RAS signaling, thereby repressing NIS and RAI uptake. Although targeted therapies such as BRAF inhibitors have shown some success in resensitizing tumors to RAI, these tumors often escape RAI sensitivity via aberrations in complementary pathways. In patients with documented response to targeted therapies, after several months, the tumor escapes (i.e., it ceases to respond and starts growing again). Several hypotheses and suggested mechanisms have been proposed to explain such escape, most of which involve overactivation of alternative pathways to overcome the drug's effect \[[@B50-cancers-11-01382],[@B51-cancers-11-01382]\].

Combining adjuvant therapies with TKIs has the potential to eliminate or delay the escape effect (i.e., resistance) and result in longer progression-free survival. Numerous genetic and signal transduction alterations have been observed in RAI-R or advanced papillary thyroid cancer (PTC) \[[@B15-cancers-11-01382],[@B21-cancers-11-01382],[@B23-cancers-11-01382]\], and simultaneous targeting of these alterations might allow more durable tumor control when combined with current TKIs.

One unique mechanism by which thyroid cancer drives RAI resistance may be via upregulation of the human epidermal receptor (HER) family of receptor tyrosine kinases, which is present in more than one-third of thyroid cancers and is positively correlated with local tumor invasiveness \[[@B52-cancers-11-01382]\]. HER2 and HER3 are key players upstream of extracellular signal-regulated kinase (ERK) and AKT, and HER2 and HER3 activate these signaling pathways. Interestingly, overexpression of HER2 and HER3 may provide a mechanism of RAI-R tumor escape for *BRAF* mutant cells treated with the BRAF inhibitor vemurafenib \[[@B53-cancers-11-01382]\]. Therefore, the addition of the HER2 inhibitor trastuzumab to vemurafenib treatment may enable patients with RAI-R tumors to overcome the escape phenomenon and experience a more durable effect from the targeted therapy \[[@B54-cancers-11-01382]\].

Anaplastic lymphoma kinase (ALK) is a recently identified kinase with the potential to contribute to aggressive disease in non-small-cell lung cancers. This kinase can undergo rearrangements---the most common is EML4-ALK fusion with echinoderm microtubule--associated protein-like 4 (*EML4*) gene---that were described in a subset of patients, who tend to be younger with more aggressive disease \[[@B55-cancers-11-01382]\]. ALK fusion proteins are known to activate various signaling pathways, such as the PI3K/AKT pathway and the MAPK pathways \[[@B56-cancers-11-01382],[@B57-cancers-11-01382]\], and aberrant activation of these ALK fusion proteins promotes proliferation and survival in cancer cells \[[@B58-cancers-11-01382]\]. ALK fusion has been demonstrated in medullary thyroid cancer and anaplastic carcinoma \[[@B59-cancers-11-01382]\]. In RAI-R DTC, EML4-ALK fusion and several other ALK translocations were identified by whole genome sequencing \[[@B60-cancers-11-01382]\]. A study of the translocation profile of ALK in DTC found ALK translocations in 11 of 498 papillary thyroid cancers (PTCs) (2.2%) and 3 of 23 diffuse sclerosing variant PTCs (13%). Combining specific ALK inhibitors such as crizotinib with standard adjuvant therapies might offer durable response in patients with ALK-positive tumors \[[@B61-cancers-11-01382]\].

Alterations in the PI3K/AKT/mTOR cascade are well documented in thyroid cancer tumorigenesis ([Figure 1](#cancers-11-01382-f001){ref-type="fig"}). The inhibition of mTOR promotes redifferentiation of thyroid cancer cells by upregulating NIS mRNA and protein expression, resulting in elevated iodine uptake through increased transcription at the level of thyroid transcription factor-1 (TTF1), which indicates TTF1 dependence for NIS expression \[[@B62-cancers-11-01382],[@B63-cancers-11-01382]\]. There is an inverse relationship between platelet-derived growth factor receptor-alpha (PDGFR-α) activation and transcriptional activity of TTF1, with PDGFR-α blockade restoring NIS expression \[[@B64-cancers-11-01382]\]. Another important positive regulator of NIS expression is PTEN, which is suppressed by oncogenic miR-21; antisense-miR-21 increases NIS expression \[[@B65-cancers-11-01382]\]. Some clinical trials have evaluated the mTOR inhibitor everolimus and the combination of sorafenib and the mTOR inhibitor temsirolimus in the treatment of RAI-R thyroid cancer. However, these studies were not designed to evaluate the change in RAI uptake or the effectiveness of combined RAI therapy with the drugs \[[@B66-cancers-11-01382],[@B67-cancers-11-01382]\]. Further clinical trials are needed to elucidate the role of mTOR inhibition in inducing radioiodine avidity.

Downstream mechanisms in the signaling pathways involved in RAI refractoriness affect the posttranslational modifications or shuttling of the transcribed NIS. Pituitary tumor transforming gene 1 (PTTG1) and PTTG-1 binding factor overexpression in thyroid cancers results in decreased NIS levels \[[@B68-cancers-11-01382]\], likely through its retention in clathrin-coated vesicles or by repressing NIS mRNA transcription \[[@B69-cancers-11-01382]\]. PI3K-AKT pathway activation in thyroid carcinoma leads to suppression of NIS glycosylation and surface translocation \[[@B70-cancers-11-01382]\]. In a novel mechanism recently described by our group, decreased expression of ribosomal machinery subunits (i.e., phosphatidylinositol glycan anchor biosynthesis class U) resulted in improper NIS post-translational processing and deregulated trafficking of the protein to the plasma membrane, resulting in increased RAI refractoriness in thyroid cancer cells \[[@B71-cancers-11-01382]\].

4.5. Other Systemic Therapies {#sec4dot5-cancers-11-01382}
-----------------------------

Phase II trials of the efficacy of various chemotherapy agents for recurrent and metastatic DTC have been reported; in these, doxorubicin was the most frequently used agent \[[@B72-cancers-11-01382]\]. No consensus has been reached for the use of a specific cytotoxic regimen in RAI-R disease, and clinical trials of cytotoxic chemotherapy, in addition to TKIs and other targeted therapies, are needed in patients with RAI-R disease \[[@B1-cancers-11-01382]\].

4.6. Targeted Therapies and Tumor Immune Microenvironment in RAI-R Thyroid Cancer {#sec4dot6-cancers-11-01382}
---------------------------------------------------------------------------------

Characterizing the immune landscape following TKI treatment in various tumor types, including thyroid cancer, has demonstrated dynamic alterations in the tumor immune microenvironment \[[@B73-cancers-11-01382],[@B74-cancers-11-01382]\]. Using a TKI that targets the Vascular endothelial growth factor-A/Vascular Endothelial Growth Factor Receptor (VEGF-A/VEGFR) axis affects regulatory T cell percentages and seems to increase PD-1 (Programmed cell death protein 1) expression, which leads to inhibition of cytotoxic T cells \[[@B73-cancers-11-01382]\]. Immune profiling of *BRAF-V600E*-positive DTC revealed high levels of PD-L1 (Programmed death-ligand 1) (53% vs. 12.5%) and human leukocyte antigen G (41% vs. 12.5%) compared with *BRAF* wild-type tumors. Furthermore, *BRAF-V600E*-positive tumors had a high level of suppressive T cell and macrophage components \[[@B74-cancers-11-01382]\]. These results show the inhibitory effects of the aberrant tyrosine kinases on the immune system, indicating the potential of TKIs to reverse them, with the combination of TKIs and immune checkpoint inhibitors seemingly an attractive regimen for patients with RAI-R DTC.

Ongoing trials are evaluating the role of TKIs in advanced RAI-R thyroid cancer, either alone or in combination with immune checkpoint inhibitors or RAI therapy \[[@B75-cancers-11-01382]\]. Sulfatinib is an oral TKI targeting VEGFR, FGFR-1 (Fibroblast growth factor receptor 1), and CSF1R (colony-stimulating factor 1 receptor); therefore, it might play a dual antiangiogenic and immunomodulatory role. The early results of NCT02614495, an open label, two-cohort, phase I and II trial of sulfatinib in RAI-R DTC, were presented in 2017. In this trial, patients were assigned to sulfatinib. Partial responses were confirmed in 3 of 12 patients with DTC; all others achieved stable disease \[[@B76-cancers-11-01382]\]. An ongoing phase IB/II trial (NCT02501096), is assessing the maximum tolerated dose of lenvatinib combined with the PD-1 inhibitor pembrolizumab in patients with solid tumors, including thyroid cancer \[[@B77-cancers-11-01382]\]. Another ongoing trial, NCT01988896, is evaluating the PD-L1 inhibitor atezolizumab combined with the MAPK inhibitor cobimetinib in patients with locally advanced or metastatic solid tumors \[[@B78-cancers-11-01382]\].

4.7. Current Recommendations for Treatment of Symptomatic RAI-R Thyroid Cancer {#sec4dot7-cancers-11-01382}
------------------------------------------------------------------------------

Current American Thyroid Association (ATA) guidelines recommend high-risk metastatic progressive (i.e., at least 20% increase in sum of longest diameter of lesions) RAI-R-DTCs not amenable to conventional therapies be considered for TKIs in specialized centers. Since immunotherapies and re-sensitization therapies are currently in the phase of clinical trials, the ATA recommends admittance into these trials if RAI-R DTCs are progressive after use of approved TKIs, such as lenvatinib or sorafenib. Molecular characterization of these lesions can help to identify and select the appropriate clinical trials. The ATA endorses the use of EBRT or radiofrequency ablation or cryoablation over surgery for symptomatic distant metastatic lesions or lesions with high risk of local complications prior to initiation of TKIs. It also advocates their use for single or multiple progressive lesions while on TKIs or other novel therapies \[[@B1-cancers-11-01382]\].

5. Current and Future Perspectives with NIS Restoration in RAI-R Thyroid Cancer Redifferentiation {#sec5-cancers-11-01382}
=================================================================================================

Novel therapies with single kinase inhibitors have been shown to re-induce iodide uptake in RAI-R thyroid cancer cells. The MEK 1/2 inhibitor selumetinib was found to reverse refractoriness to RAI in patients with advanced or metastatic DTC \[[@B8-cancers-11-01382]\]. Rothenberg et al. reported that dabrafenib, a selective inhibitor of mutant BRAF, resulted in iodide re-uptake in patients with *BRAF-V600E*-positive RAI-R PTCs \[[@B79-cancers-11-01382]\]. Sabra et al. showed that RAI therapy was ineffective against metastatic, RAS-mutated, RAI-avid FTC, but pretreatment with an MAPK inhibitor improved responsiveness to RAI therapy \[[@B39-cancers-11-01382]\]. A major advantage of this treatment with a single kinase inhibitor is its shorter treatment duration (45 days) compared with long-term administration in TKIs; thus, associated adverse effects and the development of resistance are minimized \[[@B13-cancers-11-01382],[@B80-cancers-11-01382]\].

BRAF inhibitors (e.g., dabrafenib) and MEK inhibitors (e.g., selumetinib) activate PI3K and MAP-K pathways by inducing HER3 gene expression. The HER3 inhibitor lapatinib prevents this MAPK rebound and sensitizes *BRAF-V600E*-positive thyroid cancer cells to RAF or MAP/ERK inhibitors \[[@B53-cancers-11-01382]\]. Use of a HER inhibitor in combination with a BRAF/MEK inhibitor increased sensitivity of *BRAF-V600E*-positive PTC to a BRAF/MEK inhibitor by preventing MAPK rebound and increased NIS expression \[[@B81-cancers-11-01382]\]. These findings show that HER3 signaling is accompanied by an increase in ERK in the MAPK pathway and is a possible target for treating RAI-R thyroid cancer. Currently, a phase I study (NCT01947023) is evaluating combination therapy with dabrafenib and lapatinib in patients with *BRAF* mutated RAI-R DTC \[[@B82-cancers-11-01382]\].

ERK rebound could be inactivated in a sustained manner with the use of a MEK inhibitor and by thwarting RAF reactivation in *BRAF*-mutated thyroid cancer, resulting in restoration of RAI uptake through increased NIS expression \[[@B83-cancers-11-01382]\]. This concept is currently being evaluated in a phase II clinical trial (NCT03244956) using combination of Trametinib (MEK inhibitor) and Dabrafenib (BRAF inhibitor) in RAI-R DTC patients with two independent arms of *RAS* and *BRAFV600E* mutations \[[@B84-cancers-11-01382]\].

6. Conclusions {#sec6-cancers-11-01382}
==============

Efficacy and toxicity should be considered in the choice of agents to treat RAI-R thyroid cancer. These agents include axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, and vandetanib, including the selective BRAF inhibitors vemurafenib and dabrafenib ([Table 2](#cancers-11-01382-t002){ref-type="table"}).

RAF and MEK inhibitors have shown promise in the redifferentiation of RAI-R DTC; verification of these results could improve treatment options for patients with RAI-R DTC. New targeted agents, immune checkpoint inhibitors, and combinations of agents for redifferentiation show promise and could improve the efficacy of RAI therapy for patients with RAI-R thyroid cancer.
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RTK

receptor tyrosine kinase

VEGFR

vascular endothelial growth factor receptor

PDGFR

platelet-derived growth factor receptor

RET

rearranged during transfection

HER

human epidermal growth factor receptor

PI3K

phosphoinositide 3-kinase

PTEN

phosphatase and tensin homolog

AKT

protein kinase B

mTOR

mechanistic target of rapamycin

RAS

rat sarcoma

RAF

rapidly accelerated fibrosarcoma

MAPK

mitogen-activated protein kinase

ERK

extracellular signal-regulated kinase

PAX8

paired box gene 8

TSH

thyroid stimulating hormone

TSHR

thyroid stimulating hormone receptor

PTTG1

pituitary tumor transforming gene 1

PBF

PTTG1 binding factor

PIGU

phosphatidylinositol glycan anchor biosynthesis class U

NIS

Sodium/Iodide symporter

GPI

glycosylphosphatidylinositol

PKA

protein kinase A

cAMP

cyclic adenosine monophosphate

![Redifferentiation of thyroid cancer. MAPK (mitogen-activated protein kinase) (RAS/RAF/MEK) and PI3K/AKT/mTOR are key signaling pathways in thyroid cancer pathogenesis. Signaling cascades can be blocked by new targeted therapies. The crosstalk between MAPK and PI3K through RAS is shown and represents a tumor escape mechanism from known multi-kinase inhibitors and selective inhibitors of BRAF. PI3K-AKT pathway activation leads to suppression of NIS (sodium/iodide symporter) glycosylation and surface translocation. The inhibition of mTOR promotes redifferentiation of thyroid cancer cells by upregulation of NIS mRNA and protein expression through increased transcription of TTF1. Another important positive regulator of NIS expression is PTEN. TSH (thyroid stimulating hormone) signals through the heterotrimeric G-protein complex, and through activation of cAMP increases transcription of the *NIS* gene. Aberrant activation of the MAPK signaling pathway inhibits PIGU expression and NIS basolateral transport. PTTG1 and PBF overexpression results in decreased NIS levels in thyroid cancer.](cancers-11-01382-g001){#cancers-11-01382-f001}

cancers-11-01382-t001_Table 1

###### 

Completed Phase III Clinical Trials of Agents Approved for the Treatment of Differentiated Thyroid Cancer by the U.S. Food and Drug Administration \[[@B9-cancers-11-01382],[@B10-cancers-11-01382]\].

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Parameters*                                DECISION Trial: Sorafenib                       SELECT Trial: Lenvatinib
  ------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------
  Drug targets                                Specific target: RAF\                           Specific target: FGFR\
                                              Other targets: VEGFR, c-Kit, RET, PDGFR, FLT3   Other targets: VEGFR, c-Kit, RET, PDGFR, RET-KIF5B, CCDC6-RET, NcoA4-RET rearrangement

  Patient population                          *N* = 417, randomized 1:1\                      *N* = 392, randomized 2:1\
                                              dose: 800 mg daily                              dose: 24 mg daily

  Median progression-free survival (months)   10.8 vs. 5.8 (*p* \< 0.0001)                    18.3 vs. 3.6 (*p* \< 0.001)

  Complete response                           0% vs. 0%                                       1.5% vs. 0%

  Partial response                            12.2% vs. 0.5%                                  63.2% vs. 1.5%

  Stable disease \> 23 weeks                  41.8% vs. 33.2%                                 15.3% vs. 29.8%

  Grade 3 and 4 adverse effects               Overall: 37.2% vs. 26.3%                        Overall: 75.9% vs. 9.9%

                                              Hand-foot syndrome: 20.3%                       Hypertension: 42%

                                              Hypertension: 9.7%                              Proteinuria: 10%

                                              Hypocalcemia: 5.8%                              Thromboembolic effects: 6.5%\
                                                                                              (arterial vs. venous: 2.7% vs. 3.8%)

                                              Weight loss: 5.8%                               Acute Renal failure: 1.9%

                                              Diarrhea, fatigue: 5.3%                         QT prolongation: 1.5%

                                              Rash/desquamation: 4.8%                         Hepatic failure: 0.4%

                                              Shortness of breath: 4.8%                       

  Dose reduction                              64.3%                                           67%

  Treatment discontinuation                   19%                                             14%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-11-01382-t002_Table 2

###### 

Phase I and II Trials of Multi-Kinase Inhibitors for RAI-R Thyroid Cancers.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                           Drug Targets                       Phase   Type of Thyroid Cancer                  Response Rate (Complete or Partial Response)   Median Progression Free Survival (Months)
  -------------------------------------------------------------- ---------------------------------- ------- --------------------------------------- ---------------------------------------------- -------------------------------------------
  Axitinib (Locati et al. \[[@B85-cancers-11-01382]\])           VEGFR, PDGFR, c-Kit                II      Advanced DTC, MTC                       35%                                            16.1

  Axitinib\                                                      VEGFR, PDGFR, c-Kit                II      Advanced and RAI-R DTC, MTC and ATC     30%                                            18.1
  (Cohen et al. \[[@B86-cancers-11-01382]\])                                                                                                                                                       

  Motesanib\                                                     VEGFR, PDGFR, c-Kit                II      RAI-R DTC                               14%                                            9.3
  (Sherman et al. \[[@B87-cancers-11-01382]\])                                                                                                                                                     

  Sunitinib\                                                     PDGFR. FLT3, c-Kit, VEGFR, RET     II      RAI-R DTC and MTC                       31%                                            12.8
  (Carr et al. \[[@B88-cancers-11-01382]\])                                                                                                                                                        

  Pazopanib\                                                     VEGFR, PDGFR, c-Kit                II      RAI-R DTC                               49%                                            11.7
  (Bible et al. \[[@B89-cancers-11-01382]\])                                                                                                                                                       

  Dovitinib\                                                     FGFR, VEGFR                        II      Metastatic DTC and MTC                  20.5%                                          5.4
  (Lim et al. \[[@B90-cancers-11-01382]\])                                                                                                                                                         

  Selumetinib\                                                   MEK-1/2 (one of MAPK), RAS, BRAF   II      RAI-R DTC                               3%                                             8
  (Hayes et al. \[[@B91-cancers-11-01382]\])                                                                                                                                                       

  Cabozantinib\                                                  VEGFR, RET, MET                    I       Advanced DTC                            53%                                            NR
  (Cabanillas et al. \[[@B92-cancers-11-01382]\])                                                                                                                                                  

  Cabozantinib (Cabanillas et al. \[[@B93-cancers-11-01382]\])   VEGFR, RET, MET                    II      RAI-R DTC                               40%                                            12.7

  Cabozantinib (Brose et al. \[[@B94-cancers-11-01382]\])        VEGFR, RET, MET                    II      RAI-R DTC, Advanced DTC                 54%                                            NR

  Sorafenib (Schneider et al. \[[@B95-cancers-11-01382]\])       VEGFR, PDGFR, BRAF                 II      RAI-R DTC                               31%                                            18

  Vandetanib\                                                    VEGFR, EGFR, RET                   II      RAI-R DTC                               8.3%                                           11.1
  (Leuboulleux et al. \[[@B96-cancers-11-01382]\])                                                                                                                                                 

  Dabrafenib\                                                    BRAF                               I       BRAF-positive advanced thyroid cancer   29%                                            11.3
  (Falchook et al. \[[@B97-cancers-11-01382]\])                                                                                                                                                    

  Vemurafenib\                                                   BRAF                               II      BRAF-positive RAI-R PTC                 35%                                            15.6
  (Brose et al. \[[@B98-cancers-11-01382]\])                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ATC, anaplastic thyroid cancer; DTC, differentiated thyroid cancer; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; RAI-R, radioiodine-refractory.
